Status:
UNKNOWN
CYA Versus MMF for Treatment of Moderate-Severe Psoriasis.
Lead Sponsor:
University Hospital Muenster
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Psoriasis
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
Psoriasis is an immuno-mediated skin disorder, which affects about 2-3% of the population worldwide. For moderate-severe forms of psoriasis systemic immunosuppression is the treatment of choice. This ...
Detailed Description
Not needed.
Eligibility Criteria
Inclusion
- moderate-to-severe psoriasis (PASI Score equal and greated 10)
- written informed consent
- for female patients effective birth control
Exclusion
- psoriasis arthritis
- psoriasis palmo-plantaris
- erythrodermic psoriasis
- drug-induced psoriasis
- pregnancy
- previous treatment with cyclosporine A or mycophenolate mofetil
- pregnancy
- reduced liver function
- high blood pressure
- reduced kidney function
- severe viral or bacterial infection
- 2 weeks before or after vaccinations
- innate or acquired immunodeficiency
- severe neurologic or psychiatric symptoms
- participation in other trials
- other reasons voiced by the treating physician
Key Trial Info
Start Date :
May 1 2000
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00295425
Start Date
May 1 2000
End Date
October 1 2006
Last Update
October 5 2006
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nicolas Hunzelmann
Cologne, Germany
2
Prof. Michael Sticherling
Leipzig, Germany